IU
MCID: INT064
MIFTS: 55

Intermediate Uveitis (IU)

Categories: Eye diseases, Immune diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Intermediate Uveitis

MalaCards integrated aliases for Intermediate Uveitis:

Name: Intermediate Uveitis 12 59 15
Uveitis, Intermediate 44 73
Peripheral Uveoretinitis 12
Uveitis Intermediate 55
Chronic Cyclitis 12
Iu 59

Characteristics:

Orphanet epidemiological data:

59
intermediate uveitis
Inheritance: Not applicable; Age of onset: Childhood; Age of death: normal life expectancy;

Classifications:

Orphanet: 59  
Rare eye diseases


External Ids:

Disease Ontology 12 DOID:12732
MeSH 44 D015867
NCIt 50 C35110
Orphanet 59 ORPHA279914
ICD10 via Orphanet 34 H30.2
UMLS via Orphanet 74 C0042166
UMLS 73 C0042166

Summaries for Intermediate Uveitis

MalaCards based summary : Intermediate Uveitis, also known as uveitis, intermediate, is related to uveitis and panuveitis. An important gene associated with Intermediate Uveitis is IL2RA (Interleukin 2 Receptor Subunit Alpha), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Mycophenolic acid and Azathioprine have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and endothelial, and related phenotypes are cardiovascular system and hematopoietic system

Wikipedia : 76 Intermediate uveitis is a form of uveitis localized to the vitreous and peripheral retina. Primary... more...

Related Diseases for Intermediate Uveitis

Diseases in the Uveitis family:

Autoimmune Uveitis Posterior Uveitis
Intermediate Uveitis Infectious Anterior Uveitis
Anterior Uveitis Infectious Posterior Uveitis

Diseases related to Intermediate Uveitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 395)
# Related Disease Score Top Affiliating Genes
1 uveitis 30.8 CXCR3 HLA-B IFNG IL10 IL2RA TNF
2 panuveitis 30.4 HLA-B IL10 TNF
3 drug reaction with eosinophilia and systemic symptoms 30.0 HLA-B TNF
4 acute disseminated encephalomyelitis 30.0 HLA-B IL10
5 pulpitis 29.9 IL6 TNF
6 aspergillosis 29.8 IFNG IL10 TNF
7 posterior uveitis 29.8 IFNG IL2 IL2RA IL6 TNF
8 alopecia areata 29.4 IFNG IL2 IL2RA TNF
9 dermatitis, atopic 29.3 CXCR3 IFNG IL10 IL2 IL2RA TNF
10 multiple sclerosis 29.3 CXCR3 IFNG IL10 IL2 IL2RA IL6
11 rubella 29.2 HLA-B IL10 TNF
12 aphthous stomatitis 28.9 HLA-B IL10 IL2 IL6 TNF
13 viral infectious disease 28.9 IFNG IL10 IL2 IL6 TNF
14 autoimmune disease 28.3 CXCR3 HLA-B IFNG IL10 IL2 IL2RA
15 congenital disorder of glycosylation, type iu 12.3
16 pars planitis 12.2
17 rickets 11.9
18 epileptic encephalopathy, early infantile, 36 11.5
19 factor xi deficiency 11.1
20 von willebrand's disease 11.1
21 lymphoproliferative syndrome 2 10.3 CXCR3 IL2RA
22 htlv-1 associated myelopathy/tropical spastic paraparesis 10.3 CXCR3 IL2RA
23 folliculitis 10.2 IFNG IL2RA
24 large granular lymphocyte leukemia 10.2 IFNG IL2RA
25 toxic oil syndrome 10.2 IFNG IL2RA
26 nonspecific interstitial pneumonia 10.2 CXCR3 IFNG
27 ileocolitis 10.2 IL2RA TNF
28 histoplasmosis 10.2 HLA-B IFNG
29 idiopathic bronchiectasis 10.2 HLA-B IFNG
30 macular retinal edema 10.2
31 ovarian hyperstimulation syndrome 10.2
32 indeterminate leprosy 10.2 HLA-B TNF
33 alveolar echinococcosis 10.2 HLA-B TNF
34 pustulosis palmaris et plantaris 10.2 CXCR3 TNF
35 geographic tongue 10.2 HLA-B TNF
36 glaucomatocyclitic crisis 10.2 HLA-B TNF
37 limited scleroderma 10.2 IL2 IL2RA
38 cervicitis 10.2 IL2 IL2RA
39 nontuberculous mycobacterial lung disease 10.2 HLA-B TNF
40 trichosporonosis 10.2 IFNG TNF
41 pleural tuberculosis 10.2 IFNG TNF
42 cardiac sarcoidosis 10.2 IFNG TNF
43 scleritis 10.2 IFNG TNF
44 wells syndrome 10.2 IL2 IL2RA
45 tuberculous peritonitis 10.2 IFNG TNF
46 miliary tuberculosis 10.2 IFNG TNF
47 autoimmune myocarditis 10.2 IFNG TNF
48 soft tissue sarcoma 10.2 IFNG TNF
49 staphylococcal toxic shock syndrome 10.2 IFNG TNF
50 chronic beryllium disease 10.2 IFNG TNF

Graphical network of the top 20 diseases related to Intermediate Uveitis:



Diseases related to Intermediate Uveitis

Symptoms & Phenotypes for Intermediate Uveitis

MGI Mouse Phenotypes related to Intermediate Uveitis:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.07 CXCR3 IFNG IL10 IL2 IL6 TGFBR3
2 hematopoietic system MP:0005397 10.06 CXCR3 IFNG IL10 IL2 IL2RA IL6
3 cellular MP:0005384 10.05 CXCR3 IFNG IL10 IL2 IL6 TGFBR3
4 immune system MP:0005387 10.03 CXCR3 IFNG IL10 IL2 IL2RA IL6
5 digestive/alimentary MP:0005381 9.97 IFNG IL10 IL2 IL2RA IL6 TNF
6 mortality/aging MP:0010768 9.97 CXCR3 IFNG IL10 IL2 IL2RA IL6
7 endocrine/exocrine gland MP:0005379 9.95 IFNG IL10 IL2 IL2RA IL6 TNF
8 liver/biliary system MP:0005370 9.88 IFNG IL10 IL2 IL6 TGFBR3 TNF
9 neoplasm MP:0002006 9.73 CXCR3 IFNG IL10 IL2 IL6 TNF
10 muscle MP:0005369 9.72 IFNG IL10 IL6 TGFBR3 TNF
11 reproductive system MP:0005389 9.63 IFNG IL10 IL2 IL6 TGFBR3 TNF
12 respiratory system MP:0005388 9.5 CXCR3 IFNG IL10 IL2 IL2RA IL6
13 vision/eye MP:0005391 9.1 IFNG IL10 IL2 IL2RA IL6 TNF

Drugs & Therapeutics for Intermediate Uveitis

Drugs for Intermediate Uveitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 97)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mycophenolic acid Approved Phase 4,Phase 3 24280-93-1 446541
2
Azathioprine Approved Phase 4 446-86-6 2265
3
Methotrexate Approved Phase 4,Phase 3,Phase 1,Phase 2 59-05-2, 1959-05-2 126941
4
Infliximab Approved Phase 4,Phase 1,Phase 2 170277-31-3
5
Chlorambucil Approved Phase 4 305-03-3 2708
6
Cyclophosphamide Approved, Investigational Phase 4 6055-19-2, 50-18-0 2907
7
Prednisone Approved, Vet_approved Phase 4,Phase 3 53-03-2 5865
8
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 67-73-2 6215
9
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492
10
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-02-2 5743
11
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 1177-87-3
12 Antimetabolites Phase 4,Phase 3,Phase 1,Phase 2
13 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
14 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
15 Antirheumatic Agents Phase 4,Phase 3,Phase 1,Phase 2
16 Cyclosporins Phase 4
17 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
18 Antitubercular Agents Phase 4,Phase 3
19 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 1,Phase 2
20 Immunologic Factors Phase 4,Phase 3,Phase 1,Phase 2
21 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2
22 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Antineoplastic Agents, Alkylating Phase 4
24 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Alkylating Agents Phase 4
27 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 beta-endorphin Phase 4,Phase 2
30 Adrenocorticotropic Hormone Phase 4,Phase 2
31 Melanocyte-Stimulating Hormones Phase 4,Phase 2
32 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1
33 BB 1101 Phase 4,Phase 2,Phase 3,Phase 1
34
protease inhibitors Phase 4,Phase 2,Phase 3
35 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
36 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
37 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1
38 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
39 HIV Protease Inhibitors Phase 4,Phase 2,Phase 3
40
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
41
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
42
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
43
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
44
Adalimumab Approved Phase 3 331731-18-1 16219006
45
leucovorin Approved Phase 3,Phase 1,Phase 2 58-05-9 6006 143
46
Triamcinolone Approved, Vet_approved Phase 3,Phase 1,Phase 2 124-94-7 31307
47
Fluprednisolone Approved Phase 3 53-34-9
48
Difluprednate Approved Phase 3 23674-86-4 443936
49
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 1,Phase 2 59-30-3 6037
50
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7

Interventional clinical trials:

(show top 50) (show all 64)
# Name Status NCT ID Phase Drugs
1 Multicenter Uveitis Steroid Treatment (MUST) Trial Completed NCT00132691 Phase 4 fluocinolone acetonide intraocular implant;oral corticosteroid with immunosuppressive agents as needed
2 Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients Completed NCT02764697 Phase 4 H.P. ACTHAR SUBCUTANEOUS GEL INJECTION
3 Efficacy and Safety of H.P. Acthar® Gel in Subjects With Severe Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis NIPPU Recruiting NCT03656692 Phase 4 Acthar
4 Study of the Effectiveness of Ozurdex for the Control of Uveitis Recruiting NCT02049476 Phase 4 Dexamethasone pellet
5 Myfortic for the Treatment of Non-infectious Intermediate Uveitis Completed NCT01092533 Phase 3 Myfortic;Decortin
6 Randomized, Controlled Trial to Test the Efficacy of Interferon Beta in the Treatment of Intermediate Uveitis Completed NCT00344253 Phase 3 Interferon beta;Methotrexate
7 Efficacy and Safety of Adalimumab in Subjects With Inactive Uveitis Completed NCT01124838 Phase 3 Adalimumab;Prednisone;Placebo
8 A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis Completed NCT00333814 Phase 2, Phase 3 Dexamethasone;dexamethasone;Sham injection
9 Efficacy and Safety of Adalimumab in Patients With Active Uveitis Completed NCT01138657 Phase 3 Prednisone;Placebo
10 A Controlled, Multi-center Study of the Utilization and Safety of the MK II Inserter and the Safety of the FAI Insert in Subjects With Non-infectious Uveitis Affecting the Posterior Segment of the Eye Completed NCT02748512 Phase 3 FAI insert
11 Phase III Study in Refractory Behcet's Disease Completed NCT00995709 Phase 3 AIN457;AIN457;Placebo
12 Suprachoroidal Injection of CLS-TA in Subjects Non-infectious Uveitis Completed NCT03097315 Phase 3
13 Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis Completed NCT02595398 Phase 3 4mg CLS-TA Suprachoriodal Injection;Sham Procedure
14 A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis Completed NCT01148225 Phase 3 adalimumab
15 Difluprednate Pediatric Study for the Treatment of Inflammation Post-Cataract Surgery Completed NCT01124045 Phase 3 Difluprednate ophthalmic emulsion, 0.05%;Prednisolone acetate ophthalmic suspension, 1.0%
16 A Study of Tocilizumab in Patients With Active Polyarticular Juvenile Idiopathic Arthritis Completed NCT00988221 Phase 3 Tocilizumab;Placebo
17 A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis Completed NCT00404742 Phase 3 Placebo;LX211;LX211;LX211
18 A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis Completed NCT00404612 Phase 3 Placebo;LX211;LX211;LX211
19 Safety and Efficacy of Difluprednate 0.05% for the Treatment of Anterior Uveitis Completed NCT01201798 Phase 3 Difluprednate 0.05% ophthalmic emulsion;Prednisolone acetate 1.0% ophthalmic suspension
20 Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal (FAI) Insert in Subjects With Chronic Non-infectious Posterior Uveitis Active, not recruiting NCT02746991 Phase 3 Sham Injection;FAI Insert
21 Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert Active, not recruiting NCT01694186 Phase 3 FAI insert;Sham injection
22 38 Week Extension Study to CAIN457C2303 Terminated NCT01093846 Phase 3 AIN457;AIN457;Placebo AIN457
23 Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis Terminated NCT01095250 Phase 3 AIN457;AIN457;AIN457;Placebo
24 Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis Terminated NCT01032915 Phase 3 Placebo
25 Long-term Safety of Gevokizumab in the Treatment of Patients With Chronic Non-infectious Uveitis (EYEGUARD-X) Terminated NCT02375685 Phase 3
26 Extension Study to Assess Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis Terminated NCT01103024 Phase 3
27 Safety and Efficacy Study of Gevokizumab to Treat Non-infectious Uveitis Controlled With Systemic Treatment Terminated NCT01747538 Phase 3 Placebo;Dose 1 gevokizumab;Dose 2 gevokizumab
28 Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis Terminated NCT01684345 Phase 3 Placebo;Dose 1 gevokizumab;Dose 2 gevokizumab
29 An Open-label, Rollover Study Providing Continued Dosing of Gevokizumab in Order to Assess Long-term Gevokizumab Safety Data Terminated NCT02258854 Phase 3 Dose 2 gevokizumab
30 Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis Terminated NCT01090310 Phase 3 AIN457;Placebo
31 Study to Evaluate the Long Term Use of Treatment With AIN457 for Uveitis Withdrawn NCT01327664 Phase 3
32 Safety, Tolerability, and Efficacy of AEB071 in the Treatment of Uveitis Completed NCT00615693 Phase 2 AEB071
33 Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis , Completed NCT01526889 Phase 2 LFG316;Conventional Therapy
34 Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis Completed NCT01789320 Phase 1, Phase 2 triamcinolone acetonide (Triesence®)
35 Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis Completed NCT01582880 Phase 1, Phase 2 Riboflavin
36 Topical Interferon Gamma for Macular Edema Secondary to Uveitis Completed NCT01376362 Phase 1, Phase 2 Interferon Gamma-1b
37 Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis Completed NCT02255032 Phase 2 4 mg CLS-TA;0.8 mg CLS-TA
38 Intravitreal Infliximab in Refractory Uveitis in Behcet's Disease: A Safety and Efficacy Clinical Study Completed NCT02620618 Phase 1, Phase 2 Intravitreal Infliximab
39 Safety and Efficacy of AIN457 in Noninfectious Uveitis Completed NCT00685399 Phase 2 AIN457;AIN 457;AIN457
40 Leflunomide to Treat Uveitis Completed NCT00001863 Phase 2 Leflunomide
41 Intravitreal Sirolimus as Therapeutic Approach to Uveitis Recruiting NCT01280669 Phase 2 Intravitreal injection 440mcg;Intravitreal injection of sirolimus 880mcg
42 Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis (STAR Study) Recruiting NCT02911116 Phase 2 Ustekinumab
43 ACTH as A Re-emerging theRapy for Uveitis (The ACTHAR Study) Recruiting NCT02931175 Phase 2 ACTH gel
44 Vision Restoration With a Collagen Crosslinked Boston Keratoprosthesis Unit Recruiting NCT02863809 Phase 1, Phase 2 Riboflavin;Dextran
45 Study of the Safety, Tolerability, and Bioactivity of Tocilizumab On Patients With Non-infectious UVEITIS: The STOP-UVEITIS Study Active, not recruiting NCT01717170 Phase 1, Phase 2 Tocilizumab
46 Safety and Preliminary Efficacy Study of V404 PDS in Uveitis Terminated NCT02125266 Phase 1, Phase 2 V404
47 Safety &Efficacy of CF101 to Subjects With Uveitis Withdrawn NCT01905124 Phase 2 CF101;Placebo
48 A Phase I/IIa Study for the Treatment of Uveitis With Iontophoresis Withdrawn NCT00499551 Phase 1, Phase 2
49 Sirolimus as Therapeutic Approach to Uveitis Completed NCT00908466 Phase 1 Sirolimus (rapamycin);Sirolimus (rapamycin)
50 The Treatment of Uveitic Cystoid Macular Edema With Topical Interferon Gamma Completed NCT00943982 Phase 1 Interferon Gamma 1-b

Search NIH Clinical Center for Intermediate Uveitis

Cochrane evidence based reviews: uveitis, intermediate

Genetic Tests for Intermediate Uveitis

Anatomical Context for Intermediate Uveitis

MalaCards organs/tissues related to Intermediate Uveitis:

41
Eye, Retina, Endothelial, T Cells, B Cells, Lung, Skin

Publications for Intermediate Uveitis

Articles related to Intermediate Uveitis:

(show top 50) (show all 186)
# Title Authors Year
1
Complications in Intermediate Uveitis: Prevalence, Time of Onset, and Effects on Vision in Short-Term and Long-Term Follow-Up. ( 29370567 )
2018
2
Efficacy and Safety of Mycophenolate Mofetil in the Treatment of Recalcitrant Intermediate Uveitis. ( 29652198 )
2018
3
Efficacy of Natalizumab in Intermediate Uveitis Related to Multiple Sclerosis: A Case Report. ( 29452449 )
2018
4
Primary Glomerulonephritis with Unique C4d Deposition and Concurrent Non-infectious Intermediate Uveitis: a Case Report and Literature Review. ( 29713256 )
2018
5
Optical Coherence Tomography Angiography in Intermediate Uveitis. ( 30026083 )
2018
6
Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients. ( 30099655 )
2018
7
Anterior and Intermediate Uveitis Following Yellow Fever Vaccination with Fractional Dose: Case Reports. ( 30153765 )
2018
8
Evaluation of vascular changes in intermediate uveitis and retinal vasculitis using swept-source wide-field optical coherence tomography angiography. ( 30538102 )
2018
9
Amblyopia due to intermediate uveitis as the presenting symptom of Crohn's disease in a 6-year-old boy. ( 29102673 )
2017
10
INTERMEDIATE UVEITIS ASSOCIATED WITH PERIODIC FEVER, APHTHOUS STOMATITIS, PHARYNGITIS, AND CERVICAL ADENITIS SYNDROME. ( 28570435 )
2017
11
Preoperative Inflammatory Control and Surgical Outcome of Vitrectomy in Intermediate Uveitis. ( 28465834 )
2017
12
Listeria Monocytogenes Endophthalmitis after Intermediate Uveitis and ppV for Retinal Detachment. ( 28329887 )
2017
13
Re: Niederer etA al.: Predictors of long-term visual outcome in intermediate uveitis (Ophthalmology. 2017;124:393-398). ( 28645347 )
2017
14
A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults. ( 29183563 )
2017
15
Re: Jaffe etA al.: Injectable fluocinolone acetonide long-acting implant for noninfectious intermediate uveitis, posterior uveitis, and panuveitis: 2-year results (Ophthalmology. 2016;123:1940-1948). ( 28734339 )
2017
16
Ultra-Widefield Fluorescein Angiography in Intermediate Uveitis. ( 29040047 )
2017
17
Disease Remission in Children and Adolescents with Intermediate Uveitis: A Survival Analysis. ( 29241207 )
2017
18
Cystoid Macular Edema in Retinitis Pigmentosa with Intermediate Uveitis Responded Well to Oral and Posterior Subtenon Steroid. ( 28353369 )
2017
19
Re: Jaffe etA al.: Injectable fluocinolone acetonide long-acting implant for noninfectious intermediate uveitis, posterior uveitis, and panuveitis: two-year results (Ophthalmology. 2016;123:1940-1948). ( 28335961 )
2017
20
Association between intermediate uveitis and toxocariasis in the Korean population. ( 28151857 )
2017
21
PERIPHERAL RETINOSCHISIS IN INTERMEDIATE UVEITIS. ( 28590967 )
2017
22
Intermediate uveitis: pattern of etiology, complications, treatment and outcome in a tertiary academic center. ( 28449695 )
2017
23
Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial. ( 28903965 )
2017
24
Long-term results of pars plana vitrectomy as an anti-inflammatory therapy of pediatric intermediate uveitis resistant to standard medical treatment. ( 28862736 )
2017
25
Effect of Adalimumab on Visual Functioning in Patients With Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis in the VISUAL-1 and VISUAL-2 Trials. ( 28426849 )
2017
26
Patterns of Intermediate Uveitis in Children Presenting at a Tertiary Eye Care Center in South India. ( 28936054 )
2017
27
In Response to Laovirojjanakul W, Acharya N and Gonzales JA's "Ultra-Widefield Fluorescein Angiography in Intermediate Uveitis". ( 29283787 )
2017
28
Risk of Ocular Complications in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis. ( 26712559 )
2016
29
Remission of Intermediate Uveitis: Incidence and Predictive Factors. ( 26772874 )
2016
30
Phenotypic changes of peripheral blood mononuclear cells upon corticosteroid treatment in idiopathic intermediate uveitis. ( 27989897 )
2016
31
Ocular Siderosis Subsequent to a Missed Pars Plana Metallic Foreign Body that Masqueraded as Refractory Intermediate Uveitis. ( 27849408 )
2016
32
Associations of Systemic Diseases with Intermediate Uveitis. ( 26786193 )
2016
33
Retinal Dystrophy in 6 Young Patients Who Presented with Intermediate Uveitis. ( 27157150 )
2016
34
Predictors of Long-Term Visual Outcome in Intermediate Uveitis. ( 28017424 )
2016
35
Peripheral Vasculitis, Intermediate Uveitis and Interferon Use in Multiple Sclerosis. ( 27800257 )
2016
36
A cross-sectional study of submacular thickening in intermediate uveitis and determination of treatment threshold. ( 27188332 )
2016
37
Use of Immunosuppressive Medications for Treatment of Pediatric Intermediate Uveitis. ( 27960602 )
2016
38
Influence of baseline demographic and clinical characteristics in the visual outcome of intermediate uveitis: a survival analysis. ( 27030281 )
2016
39
Ultra-wide Field Fluorescein Angiography in Retinitis Pigmentosa with Intermediate Uveitis. ( 27413510 )
2016
40
Bilateral intermediate uveitis with appearance of frosted branch angiitis and associated with Mycoplasma pneumoniae infection: case report and review of the literature. ( 27132140 )
2016
41
INFLIXIMAB THERAPY IN PATIENTS WITH NONINFECTIOUS INTERMEDIATE UVEITIS RESISTANT TO CONVENTIONAL IMMUNOMODULATORY THERAPY. ( 27681002 )
2016
42
Injectable Fluocinolone Acetonide Long-Acting Implant for Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Two-Year Results. ( 27421623 )
2016
43
Chikungunya Virus Infection Manifesting as Intermediate Uveitis. ( 28010143 )
2016
44
Intermediate uveitis: an unusual presentation of cytomegalovirus intraocular infection in an immunocompetent patient. ( 25969485 )
2015
45
Benefits of Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study. ( 26298715 )
2015
46
Discrepancy in Fluorescein Angiography and Optical Coherence Tomography Findings of Macular Edema in Intermediate Uveitis. ( 26645484 )
2015
47
Chronic candida endophthalmitis as a cause of intermediate uveitis. ( 25870216 )
2015
48
Intermediate uveitis associated with familial Mediterranean fever. ( 26487035 )
2015
49
Associations of Independent IL2RA Gene Variants with Intermediate Uveitis. ( 26133380 )
2015
50
Treatment of cystoid macular edema secondary to chronic non-infectious intermediate uveitis with an intraocular dexamethasone implant. ( 26222112 )
2015

Variations for Intermediate Uveitis

Expression for Intermediate Uveitis

Search GEO for disease gene expression data for Intermediate Uveitis.

Pathways for Intermediate Uveitis

Pathways related to Intermediate Uveitis according to GeneCards Suite gene sharing:

(show top 50) (show all 71)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.88 HLA-B IFNG IL10 IL2 IL2RA IL6
2
Show member pathways
13.73 CXCR3 IL10 IL2 IL2RA IL6 TGFBR3
3
Show member pathways
13.58 CXCR3 IFNG IL10 IL2 IL2RA IL6
4
Show member pathways
13.45 IFNG IL10 IL2 IL2RA IL6 TGFBR3
5
Show member pathways
13.32 CXCR3 IL10 IL2 IL2RA IL6 TNF
6
Show member pathways
13.27 HLA-B IFNG IL10 IL2 IL2RA IL6
7
Show member pathways
13.21 CXCR3 IL10 IL2 IL2RA IL6 TGFBR3
8
Show member pathways
12.95 IFNG IL10 IL2 IL6 TNF
9
Show member pathways
12.93 HLA-B IL2 IL2RA IL6 TNF
10 12.75 IFNG IL2 IL2RA IL6
11
Show member pathways
12.71 HLA-B IFNG IL2 IL2RA IL6 TNF
12
Show member pathways
12.7 IL2 IL2RA IL6 TNF
13
Show member pathways
12.69 HLA-B IFNG IL10 IL2 IL2RA IL6
14
Show member pathways
12.6 IFNG IL10 IL2 IL2RA TNF
15
Show member pathways
12.56 IFNG IL10 IL2 IL6 TNF
16 12.54 IFNG IL10 IL2 IL2RA TNF
17
Show member pathways
12.51 IFNG IL10 IL2 IL2RA IL6 TNF
18
Show member pathways
12.48 HLA-B IFNG IL2 TNF
19
Show member pathways
12.4 IFNG IL10 IL2 IL6 TNF
20 12.39 HLA-B IL2 IL2RA IL6 TNF
21
Show member pathways
12.37 IFNG IL10 IL2 IL2RA IL6
22
Show member pathways
12.32 IFNG IL2 IL6 TNF
23
Show member pathways
12.25 IFNG IL6 TNF
24 12.23 IFNG IL10 IL6 TNF
25 12.22 HLA-B IL6 TNF
26
Show member pathways
12.21 IL10 IL2 IL6 TNF
27
Show member pathways
12.19 IFNG IL10 TNF
28
Show member pathways
12.13 IFNG IL6 TNF
29 12.12 IFNG IL6 TNF
30 12.12 IL10 IL6 TNF
31
Show member pathways
12.05 IFNG IL10 IL2 IL2RA IL6
32
Show member pathways
12.02 IFNG IL2 IL2RA
33 12.01 IFNG IL2 IL6 TNF
34
Show member pathways
12 IFNG IL6 TNF
35
Show member pathways
11.97 IFNG IL10 IL2 IL6 TNF
36 11.95 IL10 IL6 TNF
37
Show member pathways
11.94 IFNG IL2 IL2RA
38 11.89 IFNG IL10 IL6 TNF
39 11.87 IL2RA IL6 TNF
40 11.84 IFNG IL6 TNF
41 11.8 IFNG IL2 IL6
42 11.8 IFNG IL10 IL2 IL2RA IL6 TNF
43 11.78 IFNG IL10 IL2 IL2RA IL6
44 11.76 IL10 IL6 TNF
45
Show member pathways
11.76 IFNG IL2 IL2RA TNF
46
Show member pathways
11.67 IFNG IL2 IL6 TNF
47
Show member pathways
11.64 IFNG IL2 IL2RA TNF
48 11.64 IFNG IL10 IL2 IL6 TNF
49 11.63 IFNG TGFBR3 TNF
50 11.57 IFNG IL10 IL2 IL6 TNF

GO Terms for Intermediate Uveitis

Cellular components related to Intermediate Uveitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 IFNG IL10 IL2 IL6 TGFBR3 TNF
2 extracellular space GO:0005615 9.63 IFNG IL10 IL2 IL6 TGFBR3 TNF
3 external side of plasma membrane GO:0009897 9.26 CXCR3 IL2RA TGFBR3 TNF
4 cell surface GO:0009986 9.02 CXCR3 HLA-B IL2RA TGFBR3 TNF

Biological processes related to Intermediate Uveitis according to GeneCards Suite gene sharing:

(show all 40)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.88 CXCR3 IL10 IL6 TNF
2 MAPK cascade GO:0000165 9.85 IL2 IL2RA TNF
3 positive regulation of protein phosphorylation GO:0001934 9.83 IFNG IL2 TNF
4 cellular response to lipopolysaccharide GO:0071222 9.82 IL10 IL6 TNF
5 positive regulation of DNA-binding transcription factor activity GO:0051091 9.77 IL10 IL6 TNF
6 negative regulation of inflammatory response GO:0050728 9.75 IL10 IL2 IL2RA
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.69 IFNG IL2 IL6
8 negative regulation of mitotic cell cycle GO:0045930 9.68 IL10 TNF
9 negative regulation of interleukin-6 production GO:0032715 9.68 IL10 TNF
10 positive regulation of cytokine secretion GO:0050715 9.67 IL10 TNF
11 regulation of synapse organization GO:0050807 9.67 IL10 TNF
12 positive regulation of activated T cell proliferation GO:0042104 9.67 IL2 IL2RA
13 response to glucocorticoid GO:0051384 9.67 IL10 IL6 TNF
14 negative regulation of neurogenesis GO:0050768 9.66 IL6 TNF
15 positive regulation of protein complex assembly GO:0031334 9.66 IFNG TNF
16 protein import into nucleus, translocation GO:0000060 9.65 IFNG TNF
17 positive regulation of osteoclast differentiation GO:0045672 9.65 IFNG TNF
18 positive regulation of T cell proliferation GO:0042102 9.65 IL2 IL2RA IL6
19 regulation of signaling receptor activity GO:0010469 9.65 IFNG IL10 IL2 IL6 TNF
20 positive regulation of chemokine production GO:0032722 9.64 IL6 TNF
21 positive regulation of T cell differentiation GO:0045582 9.63 IL2 IL2RA
22 positive regulation of glial cell proliferation GO:0060252 9.63 IL6 TNF
23 humoral immune response GO:0006959 9.63 IFNG IL6 TNF
24 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.62 IFNG TNF
25 negative regulation of growth of symbiont in host GO:0044130 9.62 IL10 TNF
26 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.61 IL10 TNF
27 positive regulation of immunoglobulin secretion GO:0051024 9.61 IL2 IL6
28 interleukin-2-mediated signaling pathway GO:0038110 9.59 IL2 IL2RA
29 negative regulation of lipid storage GO:0010888 9.57 IL6 TNF
30 endothelial cell apoptotic process GO:0072577 9.56 IL10 TNF
31 negative regulation of cytokine secretion involved in immune response GO:0002740 9.55 IL10 TNF
32 cytokine-mediated signaling pathway GO:0019221 9.55 IL10 IL2 IL2RA IL6 TNF
33 negative regulation of lymphocyte proliferation GO:0050672 9.54 IL2 IL2RA
34 positive regulation of neuroinflammatory response GO:0150078 9.52 IL6 TNF
35 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.43 IFNG TNF
36 receptor biosynthetic process GO:0032800 9.4 IL10 TNF
37 regulation of T cell homeostatic proliferation GO:0046013 9.37 IL2 IL2RA
38 positive regulation of vitamin D biosynthetic process GO:0060557 9.32 IFNG TNF
39 immune response GO:0006955 9.28 CXCR3 HLA-B IFNG IL10 IL2 IL2RA
40 regulation of regulatory T cell differentiation GO:0045589 9.13 IFNG IL2 IL2RA

Molecular functions related to Intermediate Uveitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.13 IL10 IL2 IL6
2 cytokine activity GO:0005125 9.02 IFNG IL10 IL2 IL6 TNF

Sources for Intermediate Uveitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....